D' cont

coronary vessels or into a peripheral vein in a human patient in need of treatment for said coronary artery disease, said therapeutically effective amount being about 0.2 μg/kg to 48 μg/kg of patient weight.

D 2

3 ~~12~~. (amended) The method of claim ~~11~~ 2, further comprising the step of administering to said human patient about 10 U/kg to 80 U/kg of heparin within ~~about 0 to~~ 30 minutes ~~prior to~~ at administering said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D 3

4 ~~13~~. (twice amended) The method of claim ~~12~~ 3, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into one or more coronary vessels.

D 4

5 ~~14~~. (amended) The method of claim ~~13~~ 4, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 24 μg/kg to 48 μg/kg.

D 5

6 ~~15~~. (twice amended) The method of claim ~~12~~ 3 wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into a peripheral vein.

D 6

7 ~~16~~. (amended) The method of claim ~~15~~ 6, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 18 μg/kg to 36 μg/kg.

Not 2 D 7

8 ~~17~~. (twice amended) A method for treating a human patient for coronary artery disease, comprising administering a single unit dose of a recombinant ~~FGF-2~~ or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose

D7 cont comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D8 ~~18~~ 9 ~~17~~ 8. (amended) The method of claim ~~17~~ 8, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

D9 ~~24~~ 15 ~~20~~ 11. (amended) The method of claim ~~20~~ 11, wherein said unit dose comprises 0.3 mg to 3.5 mg of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D10 ~~26~~ 17. (twice amended) A method for inducing angiogenesis in a heart of a human patient, comprising administering a single unit dose of a recombinant ~~FGF-2~~ FGF or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D11 ~~27~~ 18. (amended) The method of claim ~~26~~ 17, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

D12 ~~30~~ 21. (twice amended) A method for treating a human patient for a myocardial infarction, comprising administering a single unit dose of a recombinant ~~FGF-2~~ FGF or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in said human patient, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D13 23 ~~32~~. (amended) The method of claim 22 ~~31~~, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

D14 26 ~~35~~. (twice amended) A method for providing a human patient with relief from symptoms of angina, comprising administering a single unit dose of a recombinant ~~FGF-2~~ or an angiogenically active fragment or an angiogenically active mutein thereof (FGF-2) into one or more coronary vessels or into a peripheral vein in a human patient in need of relief from symptoms of angina, said unit dose comprising from about 0.008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

D15 29 ~~38~~. (amended) The method of claim 1 ~~10~~, wherein said therapeutically effective amount of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered by infusion.

D16 35 ~~44~~. (amended) A method for treating a human patient for coronary artery disease, comprising administering a therapeutically effective amount of a recombinant ~~FGF-2~~ (FGF-2) or an angiogenically active fragment or an angiogenically active mutein thereof by infusion into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for said coronary artery disease, said therapeutically effective amount being about 0.2 μg/kg to 48 μg/kg of patient weight.

D17 37 ~~46~~. (amended) The method of claim 36 ~~45~~, further comprising the step of administering to said human patient about 10 U/kg to 80 U/kg of heparin within ~~about 0 to~~ 30 minutes ~~prior to~~ administering said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

38 ~~47~~. (amended) The method of claim 37 ~~46~~, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into one or more coronary vessels.

69 D

48. (amended) The method of claim 47, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 24 μg/kg to 48 μg/kg.

49. (amended) The method of claim 46 wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is administered into a peripheral vein.

50. (amended) The method of claim 49, wherein said therapeutically effective amount of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof is about 18 μg/kg to 36 μg/kg.

51. (amended) A method for treating a human patient for coronary artery disease comprising, administering a single unit dose of a recombinant ~~FGF-2~~ FG or an angiogenically active fragment or an angiogenically active mutein thereof by infusion into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about .008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof.

52. (amended) The method of claim 51, wherein said recombinant FGF-2 has the amino acid sequence of SEQ ID NO: 2.

---

53. (amended) The method of claim 52, wherein said unit dose comprises 0.3 mg to 3.5 mg of said recombinant FGF-2 of SEQ ID NO: 2 or said angiogenically active fragment or said angiogenically active mutein thereof.

---

54. (amended) A method for inducing angiogenesis in a heart of a human patient, comprising administering a single unit dose of a recombinant ~~FGF-2~~ FG or an angiogenically active